抗HER2治疗相关超声心动图心脏功能障碍与严重结局:报告级聚类分析
基于FAERS数据库分析抗HER2治疗相关超声心动图心脏功能障碍报告信号,总体报告比值比26.64(95%CI 25.61-27.71)。589份报告中65.0%仅功能障碍、35.0%合并心血管共报告,后者严重结局调整OR 3.24(95%CI 2.14-4.95);保留5个聚类,聚类项改善模型拟合(χ2=11.34,p=0.023),但非验证性临床分类工具。
要点
- 抗HER2治疗与超声心动图心脏功能障碍存在强报告信号,总体ROR 26.64(95%CI 25.61-27.71)。
- 合并心血管共报告者严重结局风险更高,调整OR 3.24(95%CI 2.14-4.95)。
- 聚类分析仅提供补充性报告级信息,不构成验证性临床分类或预测工具。
核心结论
- 常规药物警戒分析确认抗HER2治疗与超声心动图心脏功能障碍存在强报告信号,且心血管共报告与严重结局相关。
- 报告级聚类提供补充性分辨率,但不构成经验证的临床分类或预测工具。
研究设计与样本
- 基于OpenVigil/FAERS数据的药物警戒分析,并用openFDA数据估算总体、单药和药物组的ROR与PRR。
- 聚类队列含589份唯一报告,按心血管共报告分组,采用基于Gower距离的围绕中心点划分聚类。
- 严重结局定义为死亡、住院、危及生命事件或残疾,采用多变量logistic回归和嵌套似然比检验比较模型。
主要发现
- 总体报告比值比ROR 26.64(95%CI 25.61-27.71),比例报告比PRR 25.95(95%CI 24.97-26.96)。
- 589份报告中383份(65.0%)仅功能障碍,206份(35.0%)合并心血管共报告。
- 仅功能障碍组严重结局占17.5%,合并心血管共报告组占41.7%,调整OR 3.24(95%CI 2.14-4.95)。
- 保留5个聚类;左室功能障碍合并心血管共报告聚类严重结局比例最高(52.0%),调整OR 4.18(95%CI 1.55-11.68)高于ADC相关EF下降聚类。
- 加入聚类项改善模型拟合(χ2=11.34;p=0.023)。
临床怎么用
- 使用抗HER2治疗时,应关注超声心动图相关心脏功能障碍的报告信号,尤其对合并心血管共报告的患者警惕严重结局。
- 聚类分析结果目前仅作补充性报告级参考,不应作为临床分类或预测工具直接使用。
局限性
- 聚类分析未构成经验证的临床分类或预测工具。
- 研究基于自发报告数据,存在报告偏倚和混杂等固有局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Conventional pharmacovigilance identifies drug-event reporting signals but not heterogeneity among anti-HER2 cardiac dysfunction reports. We benchmarked this association using disproportionality analysis and assessed whether report-level clustering added information beyond cardiovascular co-reporting. METHODS: We analysed OpenVigil/FAERS data. A separate openFDA analysis estimated overall, individual-drug and drug-group reporting odds ratios (RORs) and proportional reporting ratios (PRRs). The clustering cohort comprised 589 unique reports, grouped by cardiovascular co-reporting and clustered using Gower distance-based partitioning around medoids. Severe outcome comprised death, hospitalization, life-threatening events or disability. Multivariable logistic regression and a nested likelihood-ratio test compared conventional and cluster-based models. RESULTS: Echocardiography-related cardiac dysfunction was disproportionately reported with anti-HER2 therapies overall (ROR 26.64, 95% CI 25.61-27.71; PRR 25.95, 95% CI 24.97-26.96) and across evaluated drugs and groupings. Among 589 reports, 383 (65.0%) had dysfunction only and 206 (35.0%) had cardiovascular co-reporting; severe outcomes occurred in 17.5% and 41.7%, respectively (adjusted OR 3.24, 95% CI 2.14-4.95). Five clusters were retained. The LV dysfunction with cardiovascular co-reporting cluster had the highest severe outcome proportion (52.0%) and higher adjusted odds than the ADC-associated EF-decline cluster (adjusted OR 4.18, 95% CI 1.55-11.68). Adding the cluster term improved model fit (χ2 = 11.34; p = 0.023). CONCLUSIONS: Conventional analyses confirmed a strong anti-HER2 reporting signal and an association between cardiovascular co-reporting and severe outcomes. The retained clusters added complementary report-level resolution without constituting a validated clinical classification or prediction tool.
引用
- Liu J, Chen Y, Jiang Y, et al. Anti-HER2 therapy-associated echocardiography-related cardiac dysfunction and severe outcomes: Comparison of disproportionality and report-level cluster analyses. Br J Clin Pharmacol. 2026. PMID: 42705876. doi:10.1002/bcp.70810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。